Ignite Creation Date:
2024-05-06 @ 12:35 AM
Last Modification Date:
2024-10-26 @ 10:52 AM
Study NCT ID:
NCT01614093
Status:
COMPLETED
Last Update Posted:
2019-08-28
First Post:
2012-03-20
Brief Title:
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to test a single dose of intranasal oxytocin compared to placebo in a within subjects crossover design to see if oxytocin will improve satiety signaling behaviorally andor by self report compared to placebo If this single dose pilot paradigm shows an increase in satiety it may be tested in follow-up studies as a prevention or treatment for weight gain and overeating in people with schizophrenia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None